Is Statin Use Associated With Tendon Rupture? A Population-Based Retrospective Cohort Analysis

• Published in: American journal of therapeutics Vol. 22; no. 5; p. 377
• Main Authors: Contractor, Tahmeed, Beri, Abhimanyu, Gardiner, Joseph C, Tang, Xiaoqin, Dwamena, Francesca C
• Format: Journal Article
• Language: English
• Published: United States 01.09.2015
• Subjects: Adult; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage; Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects; Insurance Claim Review; Male; Middle Aged; Retrospective Studies; Risk Factors; Rupture; Tendon Injuries - epidemiology
• DOI: 10.1097/MJT.0000000000000039

Previous case reports and small studies have suggested that 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors (HMG-CoA-Is) may increase the risk of tendon rupture. We conducted a population-based retrospective cohort evaluation to better assess this relationship. From approximately 800,000 enrollees of a private insurance database, those who were aged ≤64 years with at least 1 year of continuous enrollment were selected. Exposure was defined as initiation of HMG-CoA-I after the beginning of the study period. Each exposed person was matched with 2 controls of similar age and gender. Baseline characteristics, including known risk factors for tendon rupture, were compared between exposed and control cohorts with fidelity to the study's matched design. After adjusting for differences in follow-up and baseline characteristics, incidence rate ratios for tendon rupture was assessed in HMG-CoA-I users and nonusers. A total of 34,749 exposed patients were matched with 69,498 controls. There was no difference in the occurrence of tendon ruptures in HMG-CoA-I users versus nonusers. The results remained unchanged after adjustment for age and gender. In conclusion, this population-based retrospective cohort evaluation suggests that use of HMG-CoA-Is as a group are not associated with tendon rupture.